Loading...
XSTO
SUS
Market cap162mUSD
Jul 10, Last price  
30.76SEK
1D
0.20%
1Q
-2.78%
IPO
174.64%
Name

Surgical Science Sweden AB

Chart & Performance

D1W1MN
XSTO:SUS chart
P/E
23.49
P/S
1.58
EPS
1.31
Div Yield, %
Shrs. gr., 5y
8.22%
Rev. gr., 5y
56.77%
Revenues
992m
+12.25%
41,103,21446,100,00051,800,00057,976,00065,700,000101,515,000104,799,000366,778,000802,540,000882,853,000884,087,000992,344,000
Net income
67m
-49.24%
-3,036,8581,600,0003,300,000-2,258,000-4,519,00012,598,00015,606,00086,248,000187,974,000233,972,000131,646,00066,818,000
CFO
80m
-41.85%
07,500,00013,400,0007,937,0006,878,00055,202,00023,225,00039,083,000129,487,000238,291,000137,225,00079,795,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Surgical Science Sweden AB engages in the development of simulators for laparoscopic medical training. Its products include LapSim, for procedural simulation for cholecystectomy, appendectomy, advanced suturing and anastomosis, gynecology, hysterectomy, bariatrics, and nephrectomy; EndoSim, for endoscopy simulation; and TeamSim, for realistic training of collaboration within a surgery team. The company was founded by Anders Hyltander, David Löfstrand, and Anders Larsson on July 24, 1997 and is headquartered in Gothenburg, Sweden.
IPO date
Jun 19, 2017
Employees
259
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT